← 홈

Antibody

1,904개 · ADC 1085 · Antibody 5609 · CGT 2765 · 다음 갱신 D-14 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 1,904개
AntibodyAHotEli Lilly-linkersPhase 2

EGFR inhibitor (Cetuximab, Cetuximab (EGFR inhibitor))

Advanced Solid Tumor; NSCLC · EGFR

#EGFR#Antibody#Phase2#인기#항체+5
효능 ORR 70.6%임상시험 166상태 ACTIVE
AntibodyBHotMerckVedotin ± Pe…Phase 3

Pembrolizumab (Immunotherapy, Immunotherapy (Pembrolizumab))

Melanoma (Skin Cancer); Melanoma Stage IIIB-IV · Locally Advanced Esophageal Squamous Cel

#LocallyAdvancedEsophagealSquamou#Antibody#Phase3#인기#항체+5
효능 ORR 41.6%임상시험 155상태 RECRUITING
AntibodyBHotMerckvedotin plus pembrolizumab …Phase 2

PD-1 Blocking Antibody (Pembrolizumab, Pembrolizumab (PD-1 Blocking Antibody))

Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type · PD-1

#PD-1#Antibody#Phase2#인기#항체+5
효능 ORR 75%임상시험 151상태 ACTIVE
AntibodyBHotJanssenPhase 2

Subcutaneously (Daratumumab, Daratumumab (Subcutaneously))

Primary Plasma Cell Leukemia · Primary Plasma Cell Leukemia

#PrimaryPlasmaCellLeukemia#Antibody#Phase2#인기#항체+3
효능 ORR 91.8%임상시험 147상태 RECRUITING
AntibodyAHotRochePhase 2

combination (Trastuzumab plus Pertuzumab, Trastuzumab plus Pertuzumab (combination))

Cancer; Tumors · Cancer

#Cancer#Antibody#Phase2#인기#항체+5
효능 ORR 88.6%임상시험 144상태 RECRUITING
AntibodyCHotAstraZenecaPhase 2

durvalumab + tremelimumab (STRIDE, STRIDE (durvalumab + tremelimumab))

Advanced Unresectable Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#인기#항체+5
효능 ORR 37.4%임상시험 118상태 RECRUITING
AntibodyHotRochePhase 3

1.25mg (intravitreal bevacizumab injection, intravitreal bevacizumab injection(1.25mg))

Diabetic Macular Edema · Diabetic Macular Edema

#DiabeticMacularEdema#Antibody#Phase3#인기#항체+3
효능 ORR 69.6%임상시험 116상태 ACTIVE
AntibodyAHotRocheApproved

Tocilizumab (Tocilizumab)

Multiple Myeloma (MM); Multiple Myeloma Refractory · Chronic Lymphocytic Leukemia

#ChronicLymphocyticLeukemia#Antibody#Approved#인기#항체+5
효능 ORR 95%임상시험 115상태 RECRUITING
AntibodyAHotRochePhase 3

Obinutuzumab (Obinutuzumab)

Breast Adenocarcinoma; Metastatic Breast Carcinoma · B-cell Lymphoma

#B-cellLymphoma#Antibody#Phase3#인기#항체+5
효능 ORR 100%임상시험 114상태 RECRUITING
AntibodyBHotRochePhase 3

R (Rituximab, Rituximab (R))

Primary Central Nervous System Lymphoma · B-Cell Lymphoma

#B-CellLymphoma#Antibody#Phase3#인기#항체+4
효능 ORR 95%임상시험 114상태 ACTIVE
AntibodyBHotBiologicRocheDM1 via butelase-1 with ABD…Phase 1

HERCEPTIN (MAB HER 2, MAB HER 2 (HERCEPTIN))

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Phase1#인기#항체+5
효능 ORR 91.2%임상시험 113상태 RECRUITING
AntibodyHotRochePhase 2

Bev (Bevacizumab, Bevacizumab (Bev))

Breast Cancer With Brain Metastasis; HER2-low Expressing Breast Cancer · HER2

#HER2#Antibody#Phase2#인기#항체+5
효능 ORR 77.27%임상시험 112상태 RECRUITING
AntibodyAHotMerckvedotin plus pembrolizumab …Phase 2

pembrolizumab (KEYTRUDA®, KEYTRUDA® (pembrolizumab))

Solid Tumors · Solid Tumor, Adult

#SolidTumorAdult#Antibody#Phase2#인기#항체+5
효능 ORR 93.5%임상시험 111상태 RECRUITING
AntibodyBHotMerckPhase 2

pembrolizumab or nivolumab (The combination of radiotherapy with anti-PD1, The combination of radiotherapy with anti-PD1 (pembrolizumab or nivolumab))

Melanoma · Melanoma

#Melanoma#Antibody#Phase2#인기#항체+3
효능 ORR 56.1%임상시험 110상태 ACTIVE
AntibodyHotHoffmann-La RochePhase 2

IV (Mosunetuzumab, Mosunetuzumab (IV))

B-cell Non-Hodgkin Lymphoma · B-cell Non-Hodgkin Lymphoma

#B-cellNon-HodgkinLymphoma#Antibody#Phase2#인기#항체+4
효능 ORR 87.5%임상시험 108상태 RECRUITING
AntibodyBHotMerck KGaAvedotin (EV) was the most c…Phase 3

Avelumab (Avelumab)

Non Small Cell Lung Cancer; Colorectal Cancer · Locally Advanced or Metastatic Urothelia

#LocallyAdvancedorMetastaticUroth#Antibody#Phase3#인기#항체+5
효능 ORR 74%임상시험 105상태 ACTIVE
AntibodyBHotBeiGeneVedotin, Tislelizumab, and …Phase 1

BGB-A317 (Tislelizumab, Tislelizumab (BGB-A317))

Advanced Solid Tumor · Advanced Solid Tumor

#AdvancedSolidTumor#Antibody#Phase1#인기#항체+5
효능 ORR 68.3%임상시험 105상태 RECRUITING
AntibodyCHotXin-Hua XuPhase 2

AK104 (Cadonilimab, Cadonilimab (AK104))

Non-small Cell Lung Cancer · Leptomeningeal Metastasis

#LeptomeningealMetastasis#Antibody#Phase2#인기#항체+5
임상시험 101상태 RECRUITING
AntibodyCHotRochederuxtecan plus fluoropyrim…Phase 2

trastuzumab (Herceptin, FLOT, 5-FU, leucovorin, docetaxel, oxaliplatin, 5-FU, leucovorin, docetaxel, oxaliplatin (FLOT), trastuzumab)

Adenocarcinoma of the Gastroesophageal Junction; Adenocarcinoma of the Stomach · Adenocarcinoma of the Gastroesophageal J

#AdenocarcinomaoftheGastroesophag#Antibody#Phase2#인기#항체+5
효능 ORR 61%임상시험 100상태 ACTIVE
AntibodyCMerckPhase 2

pembrolizumab (Keytruda, KEYTRUDA(R, Pembrolizumab (KEYTRUDA(R)))

Metastatic HPV-16 Positive Squamous Cell Anal Cancer · Metastatic HPV-16 Positive Squamous Cell

#MetastaticHPV-16PositiveSquamous#Antibody#Phase2#인기#항체+3
효능 ORR 78.3%임상시험 99상태 DISCONTINUED

2 / 96 페이지

← 이전다음 →